Other reports using K562 and KCL-22, cells derived from chronic myelogenous and chronic myeloid leukemias, respectively, reported similar findings according to an increment in bioenergetics parameters such as OCR when using Imatinib, a BCR-ABL inhibitor. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.